Drug Search Results
More Filters [+]

Temavirsen sodium

Alternative Names: temavirsen sodium, rg-101, rg 101, rg101
Latest Update: 2023-04-30
Latest Update Note: PubMed Publication

Product Description

Fomivirsen sodium is a 21-base phosphorothioate oligodeoxynucleotide complementary to the messenger RNA of the major immediate-early region proteins of human cytomegalovirus, and is a potent and selective antiviral agent for cytomegalovirus retinitis. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/11978144/)

Mechanisms of Action: mIR-1222 Antagonist

Novel Mechanism: Yes

Modality: N/A

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Isis|Alnylam
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Temavirsen sodium

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Hepatitis C

Phase 2: Hepatitis C, Chronic

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2016-002069-77

P3

Completed

Hepatitis C

2017-09-14

2015-004702-42

P2

Completed

Hepatitis C, Chronic

2017-09-21

2015-001535-21

P2

Completed

Hepatitis C, Chronic

2017-01-18

Recent News Events